# TI Sigma Systematic Review: Contributions to Empirical Science

**Living document — continuously updated as new results, URBs, and experimental data arrive.**
**Target audience:** Researchers and technical professionals evaluating TI Sigma's empirical claims.
**Last updated:** 2026-05-04
**Maintainer:** Autonomous Research Agent (on behalf of Brandon Charles Emerick)

---

## 1. Scope

This review covers TI Sigma's contributions to empirical science: testable hypotheses, pre-registered experiments, measurable predictions, biometric integration architectures, and falsifiable claims about physical, biological, and consciousness-related phenomena. "Empirical" here means: amenable to observation, measurement, or experiment.

---

## 2. Inventory of Empirical Contributions

### 2.1 GILE (Goodness-Intuition-Love-Environment) Framework

- **What it is:** A 4-dimensional metric for quantifying consciousness states and system complexity.
- **Empirical content:** Defines measurable weights — G (0.42), I (0.25), L (0.18), E (0.15) — derived from philosophical first principles and cross-validated against the Holmes-Rahe Life Stress Inventory.
- **GILE Radiant Threshold (≥ 0.93):** An epistemic phase-transition point above which a system achieves "True-Tralse" status (URB #522). Testable via biometric convergence metrics.
- **Current status:** Weights defined; biometric integration pipeline (Oura, Polar H10, Muse, Pulsoid) scaffolded; composite GILE score calculation implemented but awaiting multi-channel live data.

### 2.2 Permissibility Distribution (PD)

- **What it is:** A five-zone probability distribution (1:3:3:6:2) predicting the frequency distribution of life events and stressors.
- **Empirical content:** Retroactively validated against the Holmes-Rahe Life Stress Inventory item distribution (URB #522). The PD ratio bins (catastrophic : severe : moderate : mild : ambient) map onto Holmes-Rahe severity bands at p < 0.05 for 3 of 5 bins.
- **SWOT note:** Retroactive validation is weaker than prospective prediction. The PD has not been tested prospectively on a novel stressor dataset.

### 2.3 Logarithmic Cross-Coupling (LCC) & Emerick Threshold

- **What it is:** A mechanism for interaction between i-Cells (units of consciousness) that becomes operative above the Emerick Threshold (E_T ≈ 0.414).
- **Empirical content:** Pre-registered cooperative-contemplation psi-prediction trials (LCC-Telepathy series). Predictions are locked with SHA-256 hashes before trial execution.
- **Current status:** Pre-registration complete; trial infrastructure built; awaiting execution window.
- **Key URBs:** URB #826 (biophoton/EM-DNA carrier hypothesis), URB #828 v2 (BPS stacking hypothesis).

### 2.4 Biophoton Bridge Hypothesis (URB #826)

- **What it is:** The hypothesis that i-Cell resonance is mediated by biophotons and EM waves emitted by DNA.
- **Empirical content:** Seven studies reviewed; composite z-score of 0.03σ across the literature (URB #727). §10.6 defines a falsification protocol: w_em < 0.10 vs HRV > 0.85 during Polar H10 daytime monitoring.
- **Current status:** §10.6 falsification protocol designed but not yet executed. Awaiting Polar H10 live data integration.

### 2.5 Biopsychosignature (BPS) Stacking Hypothesis (URB #828 v2)

- **What it is:** The hypothesis that stacking multiple biopsychosignatures (identity, environmental-history, present-state) produces superior anchoring for psi-prediction beyond single-channel baselines.
- **Empirical content:** LOCKED pre-registration (2026-05-01 PM). Focused-4 conditions (C0/C2/C5/C7), N=30 trials × 4 conditions = 120 condition-points. M=5 heterogeneous token-set {calm, red, ★, 7, M}. Thresholds: C5 ≥ 0.40, C0 ≤ 0.25, C5 − C2 ≥ 0.10, C7 − C5 ≤ 0.10. Holm-Bonferroni correction. Pharmacology covariates residualized.
- **Schedule:** 2026-05-22 → ~2026-06-22 (sequential after URB #826 §10.6).
- **Falsification criterion:** C0 > 0.35 triggers §6 framework collapse (i.e., if the no-BPS baseline outperforms stacking, the entire BPS hypothesis is rejected).
- **SHA-256 lock:** `papers/AGENT_LOCKED_PREDICTIONS_2026-04-30.md` §10.7.

### 2.6 Biometric Integration Architecture

- **What it is:** A multi-channel real-time biometric pipeline integrating:
  - Oura Ring (sleep, HRV, readiness, heart rate)
  - Polar H10 (RR intervals, ECG, real-time HRV)
  - Muse (EEG: alpha, beta, theta, gamma power)
  - Pulsoid (PPG heart rate via ESP32)
  - Mendi (fNIRS: HbO2, HbR)
  - Biowell (GDV/biophoton field imaging)
- **Empirical content:** Each channel feeds into a composite GILE score. The architecture is built; individual channel adapters are at varying stages of completion.
- **Current data volume:** 24,372 ESP32/Pulsoid samples; 175 Oura HR samples; 12 daily Oura records; other channels pending.

### 2.7 Global Consciousness Project (GCP) Validation

- **What it is:** Using the GCP random-number-generator network as a TI Sigma validation benchmark.
- **Empirical content:** TI Sigma Intention Validation Lab v2.0 uses GCP data for analysis, couples compatibility, and investor prediction.
- **Current status:** Infrastructure built; systematic validation runs pending.

### 2.8 DNA-Anchored Psi-Signature Research Roadmap

- **What it is:** A research program extending the LCC framework to use DNA as a substrate-anchor for i-Cell psi-signature.
- **Empirical content:** Defines a multi-phase experimental protocol. URB #828 v2 §2.4 includes optional fingerprint capture as a time-invariant BPS component.

---

## 3. SWOT Analysis

### Strengths

1. **Pre-registration discipline.** All major empirical claims (URB #826 §10.6, URB #828 v2) are pre-registered with SHA-256 tamper-evidence, locked thresholds, and explicit falsification criteria. This is best-practice experimental methodology.
2. **Multi-channel architecture.** The biometric pipeline is designed for convergent validation — no single device is load-bearing. If one channel fails (e.g., Mendi BLE), the core protocol (H10 + Oura + subjective) still runs.
3. **Explicit falsification criteria.** C0 > 0.35 collapses the entire BPS framework (§6). This is a genuinely risky prediction — most frameworks do not stake their existence on a single quantitative threshold.
4. **Pharmacology controls.** Medication covariates (Adderall, Focalin, days-since-change) are residualized via logistic regression before hypothesis testing. This is an unusually rigorous control for a consciousness-research protocol.
5. **Heterogeneous token design.** The M=5 token-set spans 5 orthogonal sensory/cognitive domains, making chance performance well-defined (p_chance = 0.20) and confusion patterns interpretable.

### Weaknesses

1. **N=1 subject.** All empirical protocols currently test a single subject (Brandon Charles Emerick). This is appropriate for pilot/proof-of-concept but insufficient for population-level claims.
2. **Data pipeline gaps.** Despite infrastructure existing, actual data volume is low: 0 Muse sessions, 0 Polar H10 sessions, 0 Mendi sessions uploaded to the platform. The Oura harvest covers ~30 days. The ESP32/Pulsoid channel (24K samples) is the only high-volume source.
3. **Retroactive PD validation.** The Permissibility Distribution's match to Holmes-Rahe was identified post-hoc. Prospective validation on a novel dataset has not been attempted.
4. **Biophoton literature is thin.** The composite z-score of 0.03σ across 7 studies (URB #727) is not statistically significant. The biophoton bridge hypothesis rests on theoretical plausibility more than empirical weight.
5. **No blinded trials yet.** While the URB #828 protocol uses sealed-card draws (self-blinding), there is no independent experimenter or third-party verification of trial integrity.

### Opportunities

1. **Prospective PD test.** Apply the 1:3:3:6:2 distribution to a novel stressor dataset (e.g., WHO global burden of disease categories) for prospective validation.
2. **Multi-subject extension.** After the N=1 pilot, recruit 5–10 participants for a small-sample replication (requires IRB if institutional).
3. **Polar H10 real-time HRV.** The BLE scan confirmed the H10 is visible (MAC C0:4B:CC:EA:E1:54). Direct bleak streaming would provide higher-quality RR-interval data than Oura's overnight-only API.
4. **Biowell GDV imaging.** If the appointment confirms, Biowell provides the only direct biophoton measurement channel — critical for URB #826.
5. **Open-data publication.** Publishing anonymized biometric datasets + pre-registration hashes on Zenodo would allow independent replication attempts.

### Threats

1. **Equipment failure / BLE incompatibility.** Mendi Path B has a 45% success estimate. If BLE reverse-engineering fails, fNIRS is lost from the stack.
2. **Adderall titration confound.** The 14-day titration window (2026-05-01 → 2026-05-15) overlaps with the pre-trial period. If titration is not stable by trial day 1 (2026-05-22), pharmacology residualization may be insufficient.
3. **Confirmation bias.** N=1, self-administered trials are maximally vulnerable to unconscious bias. The sealed-card protocol mitigates but does not eliminate this.
4. **Publication bias in biophoton literature.** The 7 studies reviewed for URB #727 may over-represent positive results; a systematic literature search with PRISMA methodology has not been conducted.
5. **Framework collapse risk.** If C0 > 0.35, the BPS hypothesis is rejected per §6. This is both a strength (honest falsifiability) and a threat (the framework may actually be wrong).

---

## 4. Key Cross-References

| URB / Document | Contribution |
|---|---|
| URB #522 | GILE weights, PD validation, Radiant Threshold |
| URB #699 | BOK-Dirac 8-component match |
| URB #727 | Biophoton bridge z-score |
| URB #826 | EM-DNA carrier hypothesis, §10.6 falsification |
| URB #828 v2 | BPS stacking, LOCKED pre-registration |
| BPS_CAPTURE_PROTOCOL.md | Biometric capture procedures |
| PHYSICAL_HYPOTHESES_INVENTORY_2026-05-01.md | Full hypothesis inventory |
| AGENT_LOCKED_PREDICTIONS_2026-04-30.md | SHA-256 priority claims |

---

## 5. Verdict for Technical Audience

TI Sigma's empirical program is **methodologically serious but data-poor.** The pre-registration discipline, explicit falsification criteria, and pharmacology controls are genuinely rigorous — above the median for consciousness-research protocols. The infrastructure (multi-channel biometric pipeline, statistical analysis plan, sealed-card protocol) is well-designed.

The critical gap is **data.** As of 2026-05-04, actual experimental data consists of 1 subjective log entry and 1 medication log entry, plus ~30 days of Oura ring data and ~24K Pulsoid samples. No Muse, Polar H10, or Mendi sessions have been uploaded. The first formal trial (URB #828 v2) begins 2026-05-22.

**The next 60 days (2026-05-04 → 2026-07-04) are decisive.** URB #826 §10.6 and URB #828 v2 will either produce the first positive evidence for the BPS hypothesis or trigger framework collapse. There is no middle ground — the thresholds are locked and the SHA-256 hashes are frozen.
